Impact of Short Term Lenalidomide on Immune Response to Prevnar 13® in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL)
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Lenalidomide (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Chronic lymphocytic leukaemia; Lymphocytosis
- Focus Pharmacodynamics
- 15 Mar 2018 Status changed from recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 13 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.